Clinical Trials

130 enrolled

Locally Advanced Rectal Cancer

NCT06787183 2026-03-03

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

42 enrolled

Locally Advanced Rectal Cancer With Liver Metastases

NCT07416253 2026-02-18

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

68 enrolled

Breast Neoplasms

NCT07404176 2026-02-11

TENET

Phase 2 Enrolling by invitation

20 enrolled

EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT06370416 2026-01-28

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

41 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05036434 2026-01-23

ACCOMPLISH

Endocrine

Adrenocortical Carcinoma

NCT07349303 2026-01-21

NEOPRIME

Dermatologic

Melanoma

NCT07333287 2026-01-12

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

38 enrolled

Pancreatic Cancer Liver Metastases

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

25 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06967103 2026-01-08

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

238 enrolled

Breast Neoplasms

NCT07327021 2026-01-08

NOGA

54 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07313202 2025-12-31

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

72 enrolled

Other solid neoplasm

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

NCT07284992 2025-12-16

SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC

208 enrolled

Rectal Neoplasms

NCT06817525 2025-12-05

Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

64 enrolled

Triple Negative Breast Neoplasms

NCT07256964 2025-12-02

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

216 enrolled

Triple Negative Breast Neoplasms

NCT07252375 2025-11-26

A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma

35 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06313801 2025-11-21

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

106 enrolled

Stomach Neoplasms

NCT07243418 2025-11-21

Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study

72 enrolled

Breast Neoplasms

NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04962867 2025-10-03

NCCH2006/MK010 Trial (FORTUNE Trial)

75 enrolled

Acrocephalosyndactylia

NCT05177068 2025-10-02

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

42 enrolled

Phase 2 Enrolling by invitation

Stomach Neoplasms

NCT07121478 2025-10-01

Patients With High-grade Pancreatic Neuroendocrine Tumors

46 enrolled

EndocrineNET

Adenoma, Islet Cell, Neuroendocrine Tumors

NCT07191249 2025-09-24

A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).

Lymphoid

Lymphoma, Follicular

NCT07187908 2025-09-23

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

1,076 enrolled

Classical hematology

Primary/Secondary Prevention

NCT06388720 2025-09-15

IMGeS

82 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07171528 2025-09-12

KOV-02S

80 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05277844 2025-09-10

TARGET-01

106 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07000162 2025-08-29

LART

56 enrolled

Tumor-Agnostic

Neoplasms

NCT07136974 2025-08-22

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

280 enrolled

Breast Neoplasms

NCT07128251 2025-08-17

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

47 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

38 enrolled

Mid-low Rectal Cancer

NCT07125950 2025-08-15

SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

Advanced Breast Cancer

NCT07121322 2025-08-13

DACT-GCT

33 enrolled

Neoplasms, Germ Cell and Embryonal

NCT07100600 2025-08-11

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases

224 enrolled

CNS

Brain Neoplasms

NCT07108816 2025-08-07

A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)

52 enrolled

Resectable Stage II-IIIB NSCLC

NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

200 enrolled

Breast Neoplasms

NCT04790474 2025-07-24

IPoD-790

61 enrolled

Plasma cell

Multiple Myeloma

NCT03755141 2025-07-22

Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer

109 enrolled 7 charts

Breast Neoplasms

NCT05304546 2025-07-22

MK3475-C01

1 enrolled

Dermatologic

Melanoma, Neoplasms

NCT07046221 2025-07-20

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Esophageal Neoplasms

NCT06709859 2025-07-17

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Carcinoma, Non-Small-Cell Lung

NCT07070713 2025-07-17

Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

44 enrolled

Metastatic Colorectal Cancer With Left-sided Primary Tumor

NCT07069270 2025-07-16

A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

28 enrolled

Small Cell Lung Carcinoma

NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

36 enrolled

Unresectable Non-small Cell Lung Cancer

NCT06839144 2025-07-11

OC-POP-PT

Gynecologic

Neoplasms, Ovarian Neoplasms

NCT04864067 2025-07-01

NOAHS-ARC

73 enrolled

Adenocarcinoma, Rectal Neoplasms

NCT02078700 2025-06-25

Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.

GastrointestinalOther solid neoplasmThoracic

40 enrolled

Lung Neoplasms, Mesothelioma, Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT06394661 2025-06-23

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

109 enrolled

Breast Neoplasms

NCT06860529 2025-06-23

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

357 enrolled